Sugi Predict

Sugi Predict / Compounds / SCHEMBL5405680

SCHEMBL5405680

SCHEMBL5405680

O=c1[nH]c2ccc(NC3CCN(Cc4ccccc4)CC3)cc2[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 8/20 0.62
▸ ROCK1 Q13464 6/20 0.62
▸ CCR2 P41597 3/20 0.62
▸ ITK Q08881 1/20 0.53
▸ MCHR1 Q99705 1/20 0.53
▸ MALT1 Q9UDY8 1/20 0.52
▸ GRIN2D O15399 1/20 0.50
▸ GRIN3B O60391 1/20 0.50
▸ GRIN1 Q05586 1/20 0.50
▸ GRIN2A Q12879 1/20 0.50
▸ GRIN2B Q13224 1/20 0.50
▸ GRIN2C Q14957 1/20 0.50
▸ GRIN3A Q8TCU5 1/20 0.50
▸ PARP14 Q460N5 1/20 0.49
▸ PDK2 Q15119 1/20 0.49
▸ ACHE P22303 3/20 0.49
▸ BCHE P06276 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ LTA4H P09960 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7296357 0.85 ROCK2 (0.61) ROCK2ROCK1CCR2ITKMALT1
SCHEMBL20773510 0.80 SLC6A12 (0.67) ROCK2ROCK1MCHR1ACHEGAA
SCHEMBL4833796 0.80 ROCK2 (0.64) ROCK2ROCK1CCR2ITKMCHR1
SCHEMBL918426 0.77 KDM4E (0.66) ROCK2ROCK1CCR2MALT1ACHE
SCHEMBL5413599 0.77 ITK (0.67) ROCK2ROCK1CCR2ITKMCHR1
SCHEMBL7286870 0.77 KDM4E (0.67) ROCK2ROCK1CCR2MALT1ACHE
SCHEMBL923860 0.77 LMNA (0.68) ROCK2ROCK1CCR2MALT1ACHE
SCHEMBL5409256 0.77 ROCK2 (0.83) ROCK2ROCK1CCR2KDM4EMAPK1
SCHEMBL224917 0.77 ROCK2 (1.00) ROCK2ROCK1CCR2
SCHEMBL5418874 0.77 ROCK2 (0.63) ROCK2ROCK1CCR2ITKMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3679027-A1 DIHYDROBENZIMIDAZOLONES C4 Therapeutics, Inc. (US) 2020-07-15 — — EP claimed
WO-2019043217-A1 DIHYDROBENZIMIDAZOLONES F. HOFFMANN-LA ROCHE AG (CH) 2019-03-07 — — WO claimed
US-12365681-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2025-07-22 — — US disclosed
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-04-04 — — US disclosed
CN-111315735-B Dihydrobenzimidazolone C4医药公司 2024-03-08 — — CN disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2022-09-15 — — US disclosed
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2022-09-15 — — US disclosed
US-11254672-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2022-02-22 — — US disclosed
US-11254672-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2022-02-22 — — US disclosed
EP-3679027-A1 DIHYDROBENZIMIDAZOLONES C4 Therapeutics, Inc. (US) 2020-07-15 — — EP disclosed
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 — — US disclosed
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 — — US disclosed
WO-2019043217-A1 DIHYDROBENZIMIDAZOLONES F. HOFFMANN-LA ROCHE AG (CH) 2019-03-07 — — WO disclosed
WO-2019043217-A1 DIHYDROBENZIMIDAZOLONES F. HOFFMANN-LA ROCHE AG (CH) 2019-03-07 — — WO disclosed
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 — — US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 — — US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200207764-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 ROCK2 3195/4885ROCK1 3464/4885CCR2 2937/4885
US-12365681-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 ROCK2 3195/4885ROCK1 3464/4885CCR2 2937/4885
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 ROCK2 3195/4885ROCK1 3464/4885CCR2 2937/4885
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA ROCK2 2/4885ROCK1 1/4885CCR2 2824/4885
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 ROCK2 3195/4885ROCK1 3464/4885CCR2 2937/4885
US-11787802-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 ROCK2 3195/4885ROCK1 3464/4885CCR2 2937/4885
US-11254672-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 ROCK2 3195/4885ROCK1 3464/4885CCR2 2937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.